2 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Guard Therapeutics AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery RMC-035, Placebo - Kidney Injury Following Open-Chest Cardiac Surgery | Phase 2 | Completed | Guard Therapeutics AB | 170 | 2024-08-26 | 2025-10-02 |
| Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery RMC-035, Placebo - Acute Kidney Injury | Phase 2 | Terminated | Guard Therapeutics AB | 177 | 2022-03-31 | 2024-05-16 |
| A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery RMC-035, Placebo - Acute Kidney Injury (AKI) | Phase 1 | Completed | Guard Therapeutics AB | 13 | 2021-03-16 | 2024-04-23 |
Injections (1) · Solutions (1)
Germany (3) · Canada (2) · Czechia (2) · Spain (2) · United States (1)
Alexander Zarbock, MD (1) · Michael Reusch, MD (1) · Tobias Agervald, MD (1) · Tobias Agervald, MD PhD (1)